encorafenib + binimetinib + ribociclib

Encorafenib, binimetinib, and ribociclib are small molecule kinase inhibitors used in combination as a targeted therapy for advanced solid tumors with BRAF V600 mutations, particularly metastatic melanoma. Encorafenib is a selective ATP-competitive inhibitor of RAF kinases (including mutant BRAF V600E/K), which blocks the MAPK/ERK signaling pathway involved in cell proliferation. Binimetinib is an uncompetitive inhibitor of MEK1/2, another key component of the same pathway. Ribociclib inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), thereby blocking cell cycle progression from G1 to S phase. The triple combination aims to maximize anti-tumor activity by simultaneously targeting multiple nodes within cancer growth and survival pathways, potentially delaying resistance compared to dual or single-agent regimens[1][3][5]. This regimen has been studied primarily in patients with advanced or metastatic melanoma harboring BRAF V600 mutations.